Sihuan Pharmaceutical Issues Positive Profit Alert: Net Profit Surges Over 217% for 1H 2026
Key Highlights
- Net Profit Expected to Increase by Not Less Than 217.2%: Sihuan Pharmaceutical Holdings Group Ltd. (Stock Code: 0460) anticipates recording a net profit of not less than RMB210 million for the six months ended 30 June 2026, representing a more than threefold increase compared to the same period last year.
- Stable Revenue Performance: The Group projects a revenue of no less than RMB1,140 million, which is roughly in line with the first half of 2025, indicating a solid revenue base despite market challenges.
- Medical Aesthetics Drives Growth: The medical aesthetics segment, powered by core product Letybo® (botulinum toxin) and increasing sales of regenerative and functional medical aesthetics products (including PLLA and PCL), recorded revenue of no less than RMB680 million—a year-on-year increase of at least 16.1%. This segment contributed a segment profit of no less than RMB320 million, remaining a key profit driver.
- Innovative Drug Commercialization Progress: The Group’s innovative drug business is advancing in commercialization and internationalization, resulting in significant revenue growth and a substantial reduction in net loss.
- Substantial Share of Profits from Associate: Sihuan recognized at least RMB110 million in share of profits from an associate, primarily due to the successful IPO and listing of projects invested by the associate.
- Asset Optimization Yields Gains: The Group’s ongoing optimization and divestment of generic drug assets, in response to national volume-based procurement policies, generated gains of not less than RMB140 million and enhanced overall profitability and resource allocation efficiency.
Important Information for Shareholders
- Significant Earnings Growth: The anticipated triple-digit surge in net profit is highly price-sensitive and could positively impact the share price.
- Medical Aesthetics as a Growth Pillar: The sector’s robust performance, with both revenue and segment profit growth, reinforces the Group’s profitability and market positioning.
- Strategic Asset Realignment: Gains from divestment and streamlined operations in generics reflect proactive management against policy headwinds, supporting long-term shareholder value.
- Innovative Drugs and Internationalization: Progress in commercializing a robust pipeline and expanding internationally positions Sihuan for further growth.
- Results Subject to Final Audit: The figures are based on unaudited management accounts and may be adjusted after independent auditor and audit committee review. Final results will be published before the end of August 2026.
- Caution Advised: Shareholders and potential investors should exercise caution when trading the Company’s securities, as actual results may differ from this preliminary announcement.
Strategic Outlook
With its medical aesthetics and innovative drug businesses entering the harvest period and maintaining high-speed growth, Sihuan Pharmaceutical’s performance structure continues to optimize. The Group’s clear strategic direction, comprehensive product lineup, and accelerated internationalization efforts mark its entry into a new stage of high-quality, sustainable development. The Board remains committed to an innovation-driven and differentiated approach, aiming to deliver long-term value to shareholders and investors.
Disclaimer
The information provided above is based on a preliminary review of unaudited consolidated management accounts and may be subject to adjustments. Investors are advised to refer to the official interim results announcement for the six months ended 30 June 2026, to be released before the end of August 2026, for confirmed financial data. This article does not constitute investment advice. Please exercise caution when dealing in the securities of Sihuan Pharmaceutical Holdings Group Ltd.
四環醫藥發佈正面盈利預告：2026年上半年淨利潤大增逾217%
重點摘要
- 淨利潤預計同比增長不少於217.2%： 四環醫藥控股集團有限公司（股份代號：0460）預計截至2026年6月30日止六個月錄得不少於人民幣2.1億元的淨利潤，較去年同期大增超過三倍。
- 收入保持穩定： 集團預計期內收入不少於人民幣11.4億元，與去年同期基本持平，展現穩健的業績基礎。
- 醫美業務成為增長引擎： 旗下核心產品Letybo®（A型肉毒素）及再生醫美產品（包括PLLA及PCL）和功能型醫美產品銷售持續增長，醫美業務期內收入不少於人民幣6.8億元，按年增長不少於16.1%，並貢獻分部溢利不少於人民幣3.2億元，繼續成為集團主要盈利來源。
- 創新藥業務商業化進展： 創新藥板塊多個已獲批產品商業化及國際化順利推進，帶動收入顯著增長，淨虧損大幅收窄。
- 聯營公司貢獻利潤大增： 主要由於聯營公司所投資項目成功上市，集團期內確認來自聯營公司的分佔利潤不少於人民幣1.1億元。
- 資產優化帶來收益： 面對國家帶量採購政策對仿製藥業務的衝擊，集團持續推進仿製藥業務優化及資產整合，相關資產剝離期內錄得收益不少於人民幣1.4億元，進一步提升整體盈利能力及資源配置效率。
股東須知的要點
- 盈利大幅增長： 預期淨利潤大增為高度敏感訊息，有機會推動股價上升。
- 醫美業務表現強勁： 醫美分部收入及溢利雙升，穩固盈利能力及市場地位。
- 資產重組反映管理層積極應對： 剝離及優化仿製藥業務，提升長遠股東價值。
- 創新藥及國際化： 創新藥商業化及國際業務拓展，為集團未來增長奠定基礎。
- 數據尚待審核： 所有數據未經審計或審核委員會審閱，最終業績或有調整，詳情將於2026年8月底前公佈的中期業績公告中披露。
- 提醒謹慎投資： 股東及潛在投資者買賣公司證券時應審慎行事，因最終結果可能與本公告有所差異。
戰略展望
隨著醫美及創新藥板塊進入收穫期並保持高速增長，四環醫藥的業績結構持續優化。集團具備清晰發展路徑、完善產品線及加快國際化步伐，正式進入高質量發展新階段。董事會將繼續堅持創新驅動和差異化佈局，致力為股東及投資者創造長遠可持續回報。
免責聲明
以上資料基於未經審計綜合管理賬目初步評估，最終數據或有調整。投資者請以2026年8月底前公佈的中期業績公告為準。本文章僅供參考，並不構成投資建議。請謹慎買賣四環醫藥控股集團有限公司證券。
